Topic: checkpoint inhibitors
9. Hal Barron, GlaxoSmithKline
8. Roger Perlmutter, Merck & Co.
7. Thomas Lynch, Bristol-Myers Squibb
Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. With Merck’s Keytruda, the med shrank 71% of bladder tumors, new data show.
A phase 1 clinical trial of Ziopharm's IL-12 gene therapy and a production "switch" shows promise in recurrent glioblastoma.
The mezzanine round will fund ORIC's lead asset through phase 1b and into phase 2 and move a second program into the clinic.
Transplanting T-cells to immunotherapies could lead to better results in non-Hodgkin lymphoma, Mount Sinai scientists have found.
The asset moved into a phase 1 advanced solid tumor trial late last year but was culled from the pipeline before delivering final data.
The changes cut Celgene’s ties to ICOS and PD-1 programs that overlap with those in Bristol-Myers Squibb’s pipeline and portfolio.
Neon's personalized neoantigen vaccine coupled with Opdivo staved off cancer longer than Opdivo alone in patients with lung, bladder and skin cancer.